JAK2 and acquired polycythemia vera: Evidence from multiple studies has shown that 95% of patients with polycythaemia vera (PV) and 40–60% of patients with essential thrombocytosis and primary myelofibrosis have a gain-of-function V617F mutation in JAK2 [6–9].